Skip to main content

Day: February 5, 2021

TLC Reports Fiscal Year End 2020 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 05, 2021 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the fiscal year ended December 31, 2020 and provided a business update.“In the tumultuous year that was 2020, we were fortunate enough to have achieved early patient enrollment in the Phase II clinical trial of our postsurgical pain program before COVID-19 began its spread to the United States,” commented George Yeh, President of TLC. “And in the midst of the pandemic, we managed to complete full patient enrollment in the pivotal trial of our osteoarthritis pain program and continue the global expansion of Ampholipad™, all while initiating a clinical trial for inhalable...

Continue reading

Luckin Coffee’s Restructuring Efforts Move Forward with Commencement of its Chapter 15 Case in the United States

Coordination between the Cayman Court and the U.S. Bankruptcy Court to Protect the Interests of Stakeholders and Facilitate Luckin Coffee’s Restructuring of its Financial ObligationsAll Company Stores Remain Open and Serving Customers in China; No Material Impact on Daily Operations ExpectedCompany Continues to Meet Trade Obligations in the Ordinary Course of Business, Including Paying Suppliers, Vendors and EmployeesBEIJING, Feb. 05, 2021 (GLOBE NEWSWIRE) — The Joint Provisional Liquidators (the “JPLs”) of Luckin Coffee Inc. (the “Company”) (OTC:LKNCY), Alexander Lawson of Alvarez & Marsal Cayman Islands Limited and Wing Sze Tiffany Wong of Alvarez & Marsal Asia Limited, today filed a verified petition under chapter 15 of title 11 of the United States Code (the “Chapter 15 Petition”) with the United States Bankruptcy Court...

Continue reading

TDC: Interim Financial Report Q4 2020

Financial performance in 2020 was in line with previously communicated guidance; a flat to slight decline in EBITDA (actuals -1.6%), capex of DKK 5.5-5.9bn (actuals DKK 5.5bn). Net debt-to-EBITDA ratio was 3.7x, excluding IRFS 16, which is lower than guided (4.1x).Improved or stable commercial performance across all main products in TDC Group as well as continued cost savings resulted in a stabilised EBITDA development in Q4 (+0.4% YoY).TDC Group’s operating expenses improved by 8.7% YoY in Q4, driven by cost reductions across TDC Group, primarily in Nuuday (20.1%).Nuuday’s customer base trend in Q4 improved or remained stable compared with previous quarters, and as a result the market share development stabilisedMobile RGU base improved significantly in Q4 with positive net adds in both Consumer and Business.Improved customer trend in...

Continue reading

KESLA OYJ:N SELVITYS HALLINTO- JA OHJAUSJÄRJESTELMÄSTÄ

KESLA OYJ                                             PÖRSSITIEDOTE 5.2.2021 klo 10.00KESLA OYJ:N SELVITYS HALLINTO- JA OHJAUSJÄRJESTELMÄSTÄ Kesla Oyj:n Selvitys hallinto- ja ohjausjärjestelmästä (Corporate Governance Statement) vuodelta 2020 on luettavissa tämän tiedotteen liitteenä sekä yhtiön internetsivuilla osoitteessa http://www.kesla.com/fi/sijoittajat/hallinnointi.Myös toimielinten palkitsemisraportti ovat nähtävillä yhtiön internetsivuilla http://www.kesla.com/fi/sijoittajat/hallinnointi/palkka-ja-palkkiojarjestelma/KESLA OYJSimo SaastamoinentoimitusjohtajaLISÄTIETOJA:toimitusjohtaja Simo Saastamoinen, 040 560 9310JAKELU:Nasdaq HelsinkiKeskeiset tiedotusvälineetwww.kesla.comKesla on metsäteknologian ja materiaalikäsittelyn kehittämiseen, markkinointiin ja valmistukseen erikoistunut konepajakonserni, joka tuottaa asiakkaan alustaan...

Continue reading

Godt 1. halvår med høj omsætningsvækst og en forbedret EBITDA-margin

ChemoMetec opnåede i 1. halvår 2020/21 en omsætning på DKK 133,0 mio. svarende til en vækst på 28% i forhold til året før. EBITDA steg med 53% til DKK 67,1 mio., og EBITDA-marginen blev forbedret til nu 51%.ChemoMetec har i 1. halvår fortsat været påvirket af COVID-19, herunder den stigende smitte sidst i perioden og indførelse af vidtgående restriktioner på mange europæiske og asiatiske markeder samt i USA. Udover COVID-19 og konsekvenserne heraf har vores markeder og kunder i 1. halvår også været præget af usikkerhed som følge af valget i USA og Brexit, ligesom den faldende USD-kurs har påvirket både omsætning og indtjening i negativ retning.ChemoMetec har til trods herfor opnået en betydelig vækst og fremgang på alle væsentlige markeder – en vækst drevet af stigende volumen, herunder både flere solgte instrumenter, forbrugsvarer og...

Continue reading

SAVENCIA FROMAGE & DAIRY : CHIFFRE D’AFFAIRES ANNUEL 2020

Vendredi 5 février 2021 COMMUNIQUE DE PRESSE : chiffre d’affaires annuel 2020Croissance solide en dépit de la criseLes définitions et modalités des agrégats du type écart de structure, de change ou de croissance organique n’ont pas évolué.Elles sont définies dans le rapport financier du Groupe.Le chiffre d’affaires du Groupe Savencia Fromage & Dairy progresse au 31 décembre 2020 de 3,1% au regard de l’exercice précédent pour atteindre 5 160 millions d’euros. Cette évolution nette de153 millions d’euros résulte d’un effet de structure de 6% provenant principalement de l’intégration de CF&R à compter du 1er mai 2020, d’une croissance organique de 0,6% et d’un effet de change négatif de 3,3% en lien avec la dévaluation de la quasi-totalité des monnaies mondiales vis-à-vis de l’euro. Les principaux effets se concentrent sur les...

Continue reading

Bergman & Beving AB: Interim Report 1 April–31 December 2020

Press releaseInterim Report 1 April–31 December 2020Third quarter (1 October–31 December 2020)Revenue increased by 11 percent to MSEK 1,086 (976).EBITA increased by 84 percent to MSEK 68 (37) and the EBITA margin improved to 6.3 percent (3.8).Net profit rose by 139 percent to MSEK 43 (18) and earnings per share rose to SEK 1.60 (0.65).Cash flow from operating activities amounted to MSEK 142 (151).Nine months (1 April–31 December 2020)Revenue increased by 8 percent to MSEK 3,196 (2,970).EBITA increased by 31 percent to MSEK 198 (151) and the EBITA margin improved to 6.2 percent (5.1).Net profit rose by 43 percent to MSEK 123 (86) and earnings per share rose to SEK 4.60 (3.20).Cash flow from operating activities increased to MSEK 408 (245).Significant events since the start of the operating yearThe COVID-19 pandemic had a variety of effects...

Continue reading

Bergman & Beving AB: Delårsrapport 1 april – 31 december 2020

PressmeddelandeDelårsrapport 1 april – 31 december 2020Tredje kvartalet (1 oktober – 31 december 2020)Nettoomsättningen ökade med 11 procent till 1 086 MSEK (976).Resultatet (EBITA) ökade med 84 procent till 68 MSEK (37) och EBITA-marginalen stärktes till 6,3 procent (3,8).Resultatet efter skatt ökade med 139 procent till 43 MSEK (18) och resultatet per aktie ökade till 1,60 SEK (0,65).Kassaflödet från den löpande verksamheten uppgick till 142 MSEK (151).Nio månader (1 april – 31 december 2020)Nettoomsättningen ökade med 8 procent till 3 196 MSEK (2 970).Resultatet (EBITA) ökade med 31 procent till 198 MSEK (151) och EBITA-marginalen stärktes till 6,2 procent (5,1).Resultatet efter skatt ökade med 43 procent till 123 MSEK (86) och resultatet per aktie ökade till 4,60 SEK (3,20).Kassaflödet från den löpande verksamheten ökade till 408...

Continue reading

Consti Plc Financial Statements Bulletin for January – December 2020

CONSTI PLC FINANCIAL STATEMENTS BULLETIN 5 FEBRUARY 2021, at 8.30 a.m.Consti Plc Financial Statements Bulletin for January – December 2020PROFITABILITY CONTINUED TO IMPROVE10–12/2020 highlights (comparison figures in parenthesis 10–12/2019):·Net sales EUR 78.1 (78.3) million; change -0.2 %·EBITDA EUR 3.7 (3.6) million and EBITDA margin 4.8 % (4.7 %)·Operating profit/loss (EBIT) EUR 3.0 (2.8) million and EBIT margin 3.8 % (3.6 %)·Order backlog EUR 177.9 (185.8) million; change -4.3 %·Free cash flow EUR 3.6 (5.1) million·Earnings per share EUR 0.27 (0.25)1–12/2020 highlights (comparison figures in parenthesis 1–12/2019):·Net sales EUR 274.6 (314.8) million; change -12.8 %·EBITDA EUR 11.4 (8.1) million and EBITDA margin 4.2 % (2.6 %)·Operating profit/loss (EBIT) EUR 8.2 (4.6) million and EBIT margin 3.0 % (1.5 %)·Free cash flow EUR 18.3...

Continue reading

Consti Oyj tilinpäätöstiedote 1.1.–31.12.2020

CONSTI OYJ TILINPÄÄTÖSTIEDOTE 5.2.2021, KLO 8.30                                               Consti Oyj tilinpäätöstiedote 1.1.–31.12.2020KANNATTAVUUS JATKOI PARANEMISTAAN         10–12/2020 keskeiset tapahtumat (suluissa vertailuluvut 10–12/2019):·Liikevaihto 78,1 (78,3) milj. euroa; muutos -0,2 %·Käyttökate 3,7 (3,6) milj. euroa ja käyttökateprosentti 4,8 % (4,7 %)·Liiketulos 3,0 (2,8) milj. euroa ja liiketulosprosentti 3,8 % (3,6 %)·Tilauskanta 177,9 (185,8) milj. euroa, muutos -4,3 %·Vapaa kassavirta 3,6 (5,1) milj. euroa·Osakekohtainen tulos 0,27 (0,25) euroa1–12/2020 keskeiset tapahtumat (suluissa vertailuluvut 1–12/2019):·Liikevaihto 274,6 (314,8) milj. euroa; muutos -12,8 %·Käyttökate 11,4 (8,1) milj. euroa ja käyttökateprosentti 4,2 % (2,6 %)·Liiketulos 8,2 (4,6) milj. euroa ja liiketulosprosentti 3,0 % (1,5 %)·Vapaa kassavirta...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.